Company: REVB
Filing Date: 2025-03-06
Form Type: 10-K
Source: 0000950170-25-034584
Chunk: 53

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-03-06
Form: 10-K
Item: Item 16
Chunk 53
---
 from the first day of the preceding calendar year to the first day of the current calendar year or such lesser number as determined by our board of directors.On May 15, 2024 at the Company’s 2024 Annual Meeting of Stockholders, an amendment to the 2021 Equity Incentive Plan to increase the number of shares reserved under the Plan to 10,206 was approved.Under the 2021 Plan, stock options and stock appreciation rights are granted at exercise prices determined by the Board of Directors which cannot be less than 100% of the estimated fair market value of the common stock on the grant date. Incentive stock options granted to any stockholders holding 10% or more of the Company's equity cannot be granted with an exercise price of less than 110% of the estimated fair market value of the common stock on the grant date and such options are not exercisable after five years from the grant date.As of December 31, 2024, there were 10,142 shares available for future grants under the 2021 Plan.Restricted Stock UnitsAs of December 31, 2024 and December 31, 2023, the Company has a total of 3 Rollover RSU awards for shares of common stock outstanding, respectively. As of December 31, 2024, 3 Rollover RSU awards have fully vested but are unissued and no Rollover RSU awards have been forfeited. Each Rollover RSU award converts to one share of common stock.

 F-20

Stock OptionsThe Company has granted stock options which (i) vest fully on the date of grant; (ii) vest 25% on the one-year anniversary of the grant date or the employees hiring date, with the remainder vesting quarterly thereafter; or (iii) vest quarterly over one-year, for grants to Board of Directors, officers and employees. Stock options have a maximum term of 3 or 10 years.The activity related to stock options during the year ended December 31, 2024 is summarized as follows: 

        Shares

        Weighted-average Exercise Price

        Weighted-average Remaining Contractual Term (Years)

        Outstanding at December 31, 2023

        64

        $
        3,555.83

        Granted

        —

        —

        Exercised

        —

        —

        Expired and forfeited

        —

        —

        Outstanding at December 31, 2024